Share on StockTwits

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) were the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 20,716,430 shares, a growth of 9.8% from the March 31st total of 18,875,693 shares, Stock Ratings Network reports. Approximately 35.4% of the shares of the company are sold short. Based on an average daily trading volume, of 1,554,211 shares, the short-interest ratio is currently 13.3 days.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of ZIOPHARM Oncology from a “neutral” rating to an “outperform” rating in a research note on Wednesday, March 26th. They now have a $5.60 price target on the stock. Separately, analysts at Mizuho initiated coverage on shares of ZIOPHARM Oncology in a research note on Wednesday, March 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of ZIOPHARM Oncology to a “neutral” rating in a research note on Tuesday, March 4th.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at 3.60 on Thursday. ZIOPHARM Oncology has a one year low of $1.55 and a one year high of $5.58. The stock has a 50-day moving average of $4.17 and a 200-day moving average of $4.13. The company’s market cap is $359.3 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings data on Monday, March 3rd. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.15) by $0.06. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts predict that ZIOPHARM Oncology will post $-0.44 earnings per share for the current fiscal year.

ZIOPHARM Oncology, Inc, is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (NASDAQ:ZIOP) for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.